Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.42 |
| ▸ | F2R | P25116 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069476 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1ITGB3ITGA2B | |
| SCHEMBL7067805 | 0.89 | MMP1 (0.39) | DPP8DPP7MMP1MMP2MMP3 | |
| SCHEMBL7067808 | 0.89 | MMP1 (0.39) | DPP8DPP7MMP1MMP2MMP3 | |
| SCHEMBL7068706 | 0.87 | MMP1 (0.35) | ITGB3ITGA2BDPP8DPP7MMP1 | |
| SCHEMBL7068709 | 0.87 | MMP1 (0.35) | ITGB3ITGA2BDPP8DPP7MMP1 | |
| SCHEMBL7068976 | 0.85 | MMP1 (0.39) | MMP1MMP2MMP3MMP8APP | |
| SCHEMBL7068973 | 0.85 | MMP1 (0.39) | MMP1MMP2MMP3MMP8APP | |
| SCHEMBL7070973 | 0.84 | MMP1 (0.37) | DPP8DPP7MMP1MMP2MMP3 | |
| SCHEMBL7070970 | 0.84 | MMP1 (0.37) | DPP8DPP7MMP1MMP2MMP3 | |
| SCHEMBL7065490 | 0.82 | DPP4 (0.44) | DPP8DPP7MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | GNAO1 3698/4885GNAI3 3735/4885GNAI1 3198/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | GNAO1 3698/4885GNAI3 3735/4885GNAI1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.